文献速递淋巴瘤

剂量密集型BV-ICE方案二线治疗复发难治性经典型霍奇金淋巴瘤的单中心1/2期研究

Dose-dense brentuximab vedotin plus ifosfamide, carboplatin, and etoposide for second-line treatment of relapsed or refractory classical Hodgkin lymphoma: a single centre, phase 1/2 study.
PubMed 文献 · Lancet Haematol · 2021-01-01

该单臂开放标签1/2期研究纳入45例复发或难治性经典型霍奇金淋巴瘤患者,评估剂量密集型BV-ICE方案的安全性和活性。3-4级血液学毒性常见,包括中性粒细胞减少73%、血小板减少80%和贫血13%。

要点

  • 3-4级血液学毒性常见,中性粒细胞减少73%、血小板减少80%。

核心结论

  • 剂量密集型BV-ICE是快速给予且具有活性的挽救方案,但完全缓解率低于预设2期目标。
  • 年轻(<60岁)且适合移植的患者可考虑将该方案用于二线治疗。

研究设计与样本

  • 单臂、开放标签、1/2期研究,在华盛顿大学西雅图癌症联盟开展。
  • 纳入45例首次复发或原发难治性经典型霍奇金淋巴瘤患者,中位年龄31岁(IQR 28-45)。
  • 1期部分采用3+3剂量递增确定最大耐受剂量,2期部分评估2周期后完全缓解率。

主要发现

  • 3-4级中性粒细胞减少33例(73%),贫血6例(13%),血小板减少36例(80%)。
  • 常见3-4级非血液学毒性包括发热性中性粒细胞减少4例(9%)、脓毒症6例(13%)、ALT升高5例(11%)。
  • 严重不良事件13例(29%),治疗相关死亡1例(2%)因多器官衰竭。

关键数值与推荐

  • ICE方案为标准剂量:异环磷酰胺5 g/m2联合美司钠5 g/m2第2天24小时输注,卡铂AUC 5第2天,依托泊苷100 mg/m2第1-3天,每21天为一周期,共2周期。
  • 预设2期完全缓解率目标为78%。

临床怎么用

  • 对于年轻(<60岁)、适合自体移植的复发或难治性经典型霍奇金淋巴瘤患者,可考虑剂量密集型BV-ICE作为二线挽救方案。
  • 该方案给药快速,但需密切监测血液学毒性和感染相关不良事件。

局限性

  • 单中心、单臂研究,样本量有限(45例)。
  • 完全缓解率低于预设2期目标。
  • 跨试验比较需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Relapsed or refractory classical Hodgkin lymphoma could be treated with multiagent salvage chemotherapy followed by autologous haematopoietic stem-cell transplantation. The aim of this study is to establish the safety and activity of dose-dense brentuximab vedotin combined with ifosfamide, carboplatin, and etoposide (BV-ICE) chemotherapy in second-line treatment of classical Hodgkin lymphoma. METHODS: We conducted a single-arm, open-label, phase 1/2 study of dose-dense BV-ICE at the Seattle Cancer Care Alliance, University of Washington (Seattle, WA, USA). Eligibility criteria were age 18 years or older; diagnosis of first relapse, primary refractory classical Hodgkin lymphoma after one previous line of therapy; measurable disease of at least 1 cm in the longest axis, CT of chest, abdomen, and pelvis with PET within the past 28 days; Eastern Cooperative Oncology Group performance status of 0-1; and adequate organ function. A 3 + 3 dose escalation study was done for the phase 1 part of the trial to establish the maximum tolerated dose to be used for the phase 2 study. Brentuximab vedotin was delivered on days 1 and 8 at either 1·2 mg/kg (dose level 1) or 1·5 mg/kg (dose level 2) intravenously (capped at 150 mg) with standard dosing of ICE on days 1-3 (ifosfamide 5 g/m2 plus mesna 5 g/m2 intravenously over 24 h on day 2, carboplatin area under the curve 5 on day 2 in one intravenous injection, and etoposide 100 mg/m2 on days 1-3 in one intravenous injection per day) for two 21-day cycles. The primary endpoint was to establish the recommended phase 2 dose (phase 1 part) and complete response rate after two cycles, with a prespecified target of 78% (phase 2 part). Safety analysis was done in all enrolled participants and the primary activity analysis was done in all patients with evaluable response data. This study is registered with ClinicalTrials.gov (NCT02227199); enrolment and study treatment are complete. FINDINGS: Between Oct 16, 2014, and Feb 10, 2020, we enrolled 45 patients with a median age of 31 years (IQR 28-45). The recommended phase 2 dose of brentuximab vedotin was established to be 1·5 mg/kg. After a median follow-up of 3·1 years (IQR 1·7-4·1), 32 (74%; 95% CI 58·8-86·5) of 43 evaluable patients had complete responses after two cycles of treatment. Grade 3-4 haematological toxic effects were common, including neutropenia (33 [73%]), anaemia (six [13%]), and thrombocytopenia (36 [80%]). The most common grade 3-4 non-haematological toxic effects were febrile neutropenia (four [9%]), sepsis (six [13%]), increased alanine aminotransferase (five [11%]), hyperglycaemia (three [7%]), pulmonary embolism (two [4%]), and increased aspartate aminotransferase (two [4%]). There was one (2%) on-treatment death due to multisystem organ failure that was considered treatment related. Serious adverse events occurred in 13 (29%) patients. INTERPRETATION: Our data suggest that dose-dense BV-ICE is a rapidly administered and active salvage regimen for patients with relapsed or refractory classical Hodgkin lymphoma despite a complete response in this trial lower than the prespecified phase 2 target. Although cross-trial comparisons should be made with caution, activity results seem to be similar to previously presented brentuximab vedotin chemotherapy salvage combinations delivered over much longer durations and can be considered in young (<60 years), transplantation-eligible patients for second-line therapy. FUNDING: Seagen, Lymphoma Research Foundation, National Institutes of Health/National Cancer Institute, and generous philanthropic donations to the University of Washington from numerous individuals and families in support of lymphoma research.

来源:Lancet Haematol,查看原文。版权归原作者所有。

引用

  1. Lynch RC, Cassaday RD, Smith SD, et al. Dose-dense brentuximab vedotin plus ifosfamide, carboplatin, and etoposide for second-line treatment of relapsed or refractory classical Hodgkin lymphoma: a single centre, phase 1/2 study. Lancet Haematol. 2021. PMID: 34329577. doi:10.1016/S2352-3026(21)00170-8

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。